DO NOT SEND TO WAREHOUSE

NOTICE RE: CERTIFICATES OF CORRECTION

DATE : 7-11-03 **Paper No.:** 17

TO : **Supervisor, Art Unit** 1615

SUBJECT : Certificate of Correction Request in Patent No.: 6294197

A response to the following question is requested with respect to the accompanying request for a certificate of correction.

With respect to the change(s) requested, correcting Office and/or Applicant's errors, should the patent read as shown in the certificate of correction? No new matter should be introduced, nor should the scope or meaning of the claims be changed.

PLEASE COMPLETE THIS FORM AND RETURN WITH FILE, WITHIN 7 DAYS, TO CERTIFICATES OF CORRECTION BRANCH - PK 3-915/922 PALM LOCATION 7580 - TEL. NO. 305-8309

Michelle Williams

THANK YOU FOR YOUR ASSISTANCE!

Note your decision by placing a check mark in the appropriate box below, indicating whether all changes requested in the Request for Certificate of Correction should be applied. Please specify which changes should not be applied and indicate the reason(s) for denial, in the "Comments" section below.

☑ **YES** ☐ **NO**

☐ **Comments:** _____

THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Supervisor 1615 **Art Unit**

Case: 4-20921/A

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO : US 6,294,197 B1
DATED: September 25, 2001
INVENTOR(S) : WAGNER ET AL.

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page Item (57)

~~Page 1~~, Abstract, should read:

--The present invention is concerned with solid oral dosage forms comprising a) an active agent selected from valsartan and optionally HCTZ, and b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods. --

Lines 1 thru 4

Column 5

line 52, should read:

--individually or together to particle sizes from about 0.1μ to --

Column 6

line 15, should read:

--minimum compaction force. Such a rapid disintegration--

line 49, (line 4 of paragraph before last) should read:

--a sieve under mechanical pressure. More preferably, the--

Column 9

Example 3, table should read:

Formula	
valsartan	80.0 mg (40%)
AEROSOL 200	10.0 MG (5%)
L-HPC* L-11	87.0 mg (43%)
Magnesium Stearate	3.0 mg (1.5%)
AVICEL PH-301	10.0 mg (5%)
L-HPC* L-21	5.0 mg (2.5%)
AEROSIL 200	1.0 mg (0.5%)
Talc	2.0 mg (1.0%
Magnesium Stearate	2.0 mg (1.0%)
	200.0 mg

*hydroxypropyl cellulose

MAILING ADDRESS OF SENDER:
Diane P. Tso
Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6807

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO : US 6,294,197 B1
DATED: : September 25, 2001
INVENTOR(S) : WAGNER ET AL.

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 10,
line 31 ~~(claim 2, line 1)~~ should read:
--A compressed solid oral dosage form according to claim 1 wherein--
line 42 ~~(claim 5, line 1)~~ should read:
--A compressed solid dosage form according to claim 1--
line 44 ~~(claim 6, line 1)~~ should read:
--A compressed solid dosage form according to claim 1--

Column 11,
line 7 ~~(claim 14, line 1)~~ should read:
--A compressed solid dosage form according to claim 12--
line 47 ~~(claim 26, line 4)~~, claim 26, should read:
-- insufficiency, peripheral vascular disease, stroke, left ventricular --
line 50 ~~(claim 26, line 7)~~, should read:
-- compressed solid dosage form as defined in claim 1 to a host in need --
line 51 (claim 26, line 8), should read:
-- of such treatment. --
line 56 (claim 29, line 1), should read:
--A process of forming a compressed solid dosage form--

Case: 4-20921/A

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO : US 6,294,197 B1
DATED: : September 25, 2001
INVENTOR(S) : WAGNER ET AL.

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Page 1, Abstract should read:

--The present invention is concerned with solid oral dosage forms comprising a) an active agent selected from valsartan and optionally HCTZ, and b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods. --

Column 5

line 52, should read:

--individually or together to particle sizes from about 0.1μ to --

Column 6

line 15, should read:

--minimum compaction force. Such a rapid disintegration--

line 49, (line 4 of paragraph before last) should read:

--a sieve under mechanical pressure. More preferably, the--

Column 9

Example 3, table should read:

Formula	
valsartan	80.0 mg (40%)
AEROSOL 200	10.0 MG (5%)
L-HPC* L-11	87.0 mg (43%)
Magnesium Stearate	3.0 mg (1.5%)
AVICEL PH-301	10.0 mg (5%)
L-HPC* L-21	5.0 mg (2.5%)
AEROSIL 200	1.0 mg (0.5%)
Talc	2.0 mg (1.0%
Magnesium Stearate	2.0 mg (1.0%)
	200.0 mg

*hydroxypropyl cellulose

MAILING ADDRESS OF SENDER:
Diane P. Tso
Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6807

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO : US 6,294,197 B1
DATED: : September 25, 2001
INVENTOR(S) : WAGNER ET AL.

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 10,
line 31 (claim 2, line 1) should read:
--A compressed solid oral dosage form according to claim 1 wherein--
line 42 (claim 5, line 1) should read:
--A compressed solid dosage form according to claim 1--
line 44 (claim 6, line 1) should read:
--A compressed solid dosage form according to claim 1--

Column 11,
line 7 (claim 14, line 1) should read:
--A compressed solid dosage form according to claim 12--
line 47 (claim 26, line 4), claim 26, should read:
-- insufficiency, peripheral vascular disease, stroke, left ventricular --
line 50 (claim 26, line 7), should read:
-- compressed solid dosage form as defined in claim 1 to a host in need --
line 51 (claim 26, line 8), should read:
-- of such treatment. --
line 56 (claim 29, line 1), should read:
--A process of forming a compressed solid dosage form--

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,294,197 B1
DATED : September 25, 2001
INVENTOR(S) : Robert Frank Wagner et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page,
Item [57], **ABSTRACT**,
Lines 1 thru 4, should read
-- The present invention is concerned with solid oral dosage forms comprising a) an active agent selected from valsartan and optionally HCTZ, and b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods. --

Column 5,
Line 52, should read -- individually or together to particle sizes from about 0.1μ to --

Column 6,
Line 15, should read -- minimum compaction force. Such a rapid disintegration --
Line 49, should read -- a sieve under mechanical pressure. More preferably, the --

Column 9,
Example 3, table should read

Formula	
valsartan	80.0 mg (40%)
AEROSOL 200	10.0 MG (5%)
L-HPC* L-11	87.0 mg (43%)
Magnesium Stearate	3.0 mg (1.5%)
AVICEL PH-301	10.0 mg (5%)
L-HPC* L-21	5.0 mg (2.5%)
AEROSIL 200	1.0 mg (0.5%)
Talc	2.0 mg (1.0%
Magnesium Stearate	2.0 mg (1.0%)
	200.0 mg

*hydroxypropyl cellulose

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,294,197 B1
DATED : September 25, 2001
INVENTOR(S) : Robert Frank Wagner et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 10,
Line 31, should read -- A compressed solid oral dosage from according to claim 1 wherein --
Lines 42 and 44, should read -- A compressed solid dosage form according to claim 1 --

Column 11,
Line 7, should read -- A compressed solid dosage form according to claim 12 --
Line 47, should read -- insufficieny, peripheral vascular disease, stroke, left ventricular --
Line 50, should read -- compressed solid dosage form as defined in claim 1 to a host in need --
Line 51, should read -- of such treatment. --
Line 56, should read -- A process of forming a compressed solid dosage form --

Signed and Sealed this

Ninth Day of September, 2003

JAMES E. ROGAN
Director of the United States Patent and Trademark Office